Value-Based Pricing of Medicines Explained

Value-based pricing is an approach to setting the cost of a medicine based on the therapeutic and economic benefit it provides to patients, rather than relying solely on manufacturing costs or what the market will bear. Under this model, a medicine that significantly improves survival or quality of life may justify a higher price, while one that offers only marginal benefits over existing treatments would be priced lower. This approach relies heavily on Health Technology Assessment (HTA), a process that evaluates the clinical and economic value of health interventions. In South Africa, while the Single Exit Price (SEP) framework regulates transparent transactional pricing, value-based principles are increasingly discussed in broader health policy to ensure that the procurement of medicines yields commensurate health benefits.

Pricing to Measured Benefit

To implement value-based pricing, health systems must first quantify "value." This is commonly achieved through pharmacoeconomic modelling, which compares a new medicine to the current standard of care. A central metric in this process is the Quality-Adjusted Life Year (QALY), which combines both the length of life and the quality of life into a single measure. Health systems often calculate an Incremental Cost-Effectiveness Ratio (ICER), which represents the additional cost of a new medicine per additional QALY gained compared to an alternative.

If a medicine's ICER falls below a predetermined threshold set by a health authority or insurer, it is generally considered cost-effective and eligible for reimbursement. If the price is too high relative to its measured benefit, the payer may negotiate a lower price or decline to cover it. This process aims to ensure that limited healthcare budgets are allocated to interventions that offer the greatest health return, theoretically driving innovation toward medicines that deliver meaningful clinical advantages rather than minor variations of existing therapies.

Managed-Entry and Outcomes-Based Agreements

Because predicting a medicine's real-world performance from clinical trial data is inherently uncertain, payers and pharmaceutical companies frequently use managed-entry agreements (MEAs) to bridge the gap. These are contractual arrangements that allow a medicine to enter the market while managing financial risk and clinical uncertainty. MEAs generally fall into two categories: financial-based and performance-based.

Financial-based agreements are more common and involve straightforward mechanisms like discounts, rebates, or volume caps that limit the total financial exposure of the health system. Performance-based agreements, often called outcomes-based agreements, are more complex. Under these contracts, the final cost of the medicine is linked to its real-world performance in patients. For example, a payer might only pay for a targeted therapy if a patient demonstrates a measurable response after a set period; if the patient does not respond, the manufacturer provides a refund. These agreements are intended to share the financial risk between the manufacturer and the payer, ensuring that the health system only pays for the "value" it actually receives.

Criticisms and Practical Limits

Despite its theoretical appeal, value-based pricing and outcomes-based agreements face significant practical limitations and criticisms. The most prominent challenge is data collection. Performance-based agreements require robust health information systems to accurately track patient outcomes over time. Many health systems lack the integrated electronic health records or administrative capacity to monitor whether a patient responded to a treatment, making these agreements difficult to enforce.

Methodological challenges also arise when attempting to isolate the effect of a single medicine. A patient's health outcome is influenced by numerous factors, including diet, concurrent conditions, and the quality of general care. Determining whether a treatment's success or failure is solely attributable to the medicine is often scientifically impossible in a real-world setting.

Furthermore, the confidentiality of these agreements is heavily criticized. Because payers negotiate discounts and rebates secretly to prevent other countries or organisations from demanding the same low prices, the true transaction prices of medicines are obscured. This lack of transparency makes it difficult to understand the actual cost of healthcare and can lead to inequities, where less wealthy health systems cannot negotiate comparable terms. Critics also argue that relying on metrics like QALYs can disadvantage medicines for rare diseases or chronic conditions, where the cost per QALY is inherently higher.

Balancing Transparency and Cost-Effectiveness

The tension between value-based pricing and transparent, accessible medicine costs remains an ongoing challenge for global health regulators. While confidential agreements may secure lower prices for specific health systems, they undermine the principle of transparent pricing that many patient advocates and researchers rely upon. In South Africa, the transparent Single Exit Price framework means that patients searching tools like HealthSA for medicine prices and SAHPRA registration statuses see a regulated, fixed cost, even as global debates about the underlying value of those medicines continue. Balancing the desire to reward therapeutic innovation with the need to maintain affordable, transparent access to essential medicines requires continuous negotiation between regulators, payers, and manufacturers.